Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of (September
2018)
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
6 September 2018
BOARD APPOINTMENTS
AstraZeneca
PLC (the Company) today announced the following Board and Board
Committee appointments.
New Non-Executive Director
With
effect from 1 October 2018, Joseph G. Peter (Joe) is appointed as a
Non-Executive Director and a member of the Audit Committee.
Biographical details for Joe Peter are provided below.
Leif
Johansson, Chairman of AstraZeneca, said: "We are very pleased to
welcome Joe Peter to AstraZeneca's Board. His long and
successful executive career in the automotive industry, his finance
expertise and extensive global experience, particularly in Japan
and Asia more broadly, will enable him to make a significant
contribution to AstraZeneca's future success."
Senior independent Non-Executive Director and Chairman of the Audit
Committee
As
previously announced, Rudy Markham intends to retire from the Board
at the conclusion of the Company's 2019 Annual General Meeting.
Succession plans for his role as senior independent Non-Executive
Director and Chairman of the Audit Committee are as
follows:
With
effect from 1 January 2019, Graham Chipchase will become senior
independent Non-Executive Director of the Company. Mr
Chipchase has served as a Director for six years. He has chaired
the Remuneration Committee and been a member of the Nomination and
Governance Committee since April 2015, having previously served as
a member of the Audit Committee from 2012 to 2014.
With
effect from 1 March 2019, Philip Broadley will become Chairman of
the Audit Committee. Mr Broadley became a Director and a
member of the Audit Committee in April 2017.
Remuneration Committee; Nomination and Governance
Committee
With
effect from 1 December 2018, Philip Broadley will become a member
of the Remuneration Committee and with effect from 1 March 2019, he
will become a member of the Nomination and Governance
Committee.
Joe Peter - biographical details
Joseph
G. Peter (Joe) recently retired as the Chief Financial Officer for
Nissan Motor Company, a position he held for nine years. His
wide-ranging role encompassed responsibility for the full financial
strategy of the corporation and working closely with operational
and regional management. Since 2009, he was responsible for
the company's global Finance activity including Control,
Accounting, Treasury, Investor Relations, Tax and M&A
support. In addition, Mr Peter had operational and P&L
responsibility for Nissan's global sales finance business and was
also responsible for the overall administration of Nissan's
affiliated companies and its global IS/IT operations. He was
a member of Nissan's Executive Committee and Chairman of the Board
of Directors at Nissan's sales finance companies located in Japan,
United States of America and Mexico.
More
than half of Mr Peter's 35 years in the automotive industry were
spent working in positions outside the USA, in financial and
executive roles in many countries including Mexico, Sweden, South
Korea, China, and Japan. In October 2009, he moved to Japan
to join Nissan as the Chief Financial Officer. Prior to this move,
he spent 25 years with General Motors, rising through the company
to become Vice President and Chief Financial Officer of the North
American and International Regions.
Mr
Peter earned both his MBA and BS in Corporate Finance from Wayne
State University.
He is a
member of the CNBC Global CFO Council.
In
relation to Mr Peter's appointment, no disclosure obligations arise
under paragraphs (2) to (6) of LR 9.6.13 R of the UK Listing
Authority's Listing Rules. In respect of paragraph (1) of LR
9.6.13 R, Mr Peter served as a Director of PJSC AVTOVAZ until
2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide.
For more information, please visit www.astrazeneca.com
and follow us on Twitter
@AstraZeneca.
|
Media
Relations
|
|
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
Cardiovascular;
Metabolism
|
+44 203
749 5711
|
|
Nick
Stone
|
Respiratory;
Renal
|
+44 203
749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Retail
Investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 7277
|
|
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
06 September
2018
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|